Yan Fu, Qingqing Xu, Jinqiang Zhang, Chuanzhi Kang, Changgui Yang, Lumei Guo, Chenggang Zhang, Tao Zhou, Chenghong Xiao
{"title":"Identifying the quality markers and optimizing the processing of Gastrodiae rhizoma to treat brain diseases.","authors":"Yan Fu, Qingqing Xu, Jinqiang Zhang, Chuanzhi Kang, Changgui Yang, Lumei Guo, Chenggang Zhang, Tao Zhou, Chenghong Xiao","doi":"10.3389/fphar.2024.1396825","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastrodiae rhizoma (GR) refers to the dried tuber of <i>Gastrodia elata</i> Bl. and has been used for many centuries to treat brain diseases, such as Alzheimer's disease, major depressive disorder, and cerebral ischemia. However, the processing of GR is complex and varied, resulting in unstable clinical treatment effects. The processing protocols significantly affect the active ingredients and curative effects of GR. We can optimize the processing of GR by identifying quality markers to treat brain diseases.</p><p><strong>Methods: </strong>Fresh tubers of <i>G. elata</i> Bl. were processed under eight different protocols, and their resulting contents of potentially bioactive compounds were compared using liquid chromatography mass spectrometry to screen the potential quality markers of GR through stoichiometric analysis. The potential quality markers of GR targeting Alzheimer's disease, major depressive disorder, and cerebral ischemia were identified by network pharmacology, and the potentially neuroprotective effects of these components were validated through simulated docking to likely protein targets. Finally, a fit degree analysis was carried out using different composition ratios and proportions of the disease component degree value, and the therapeutic effects of different processing methods on Alzheimer's disease, major depressive disorder, and cerebral ischemia were outlined clearly.</p><p><strong>Results: </strong>We identified 32 potential therapeutic components and screened 13 quality markers in GR, of which five quality markers (galactinol, glucosyringic acid, parishins C and E, and S-(4-hydroxybenzyl)-glutathione) showed efficacy against all three brain diseases. Furthermore, steaming and microwave-drying during processing can optimize the components of these quality markers for treating the three diseases.</p><p><strong>Conclusion: </strong>Processing protocols significantly affect the therapeutic components of GR and may also impact its effectiveness in treating brain diseases. Accordingly, optimizing the processing methods of GR to correspond to different therapeutic purposes may improve its efficacy against brain diseases.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1396825"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576197/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1396825","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gastrodiae rhizoma (GR) refers to the dried tuber of Gastrodia elata Bl. and has been used for many centuries to treat brain diseases, such as Alzheimer's disease, major depressive disorder, and cerebral ischemia. However, the processing of GR is complex and varied, resulting in unstable clinical treatment effects. The processing protocols significantly affect the active ingredients and curative effects of GR. We can optimize the processing of GR by identifying quality markers to treat brain diseases.
Methods: Fresh tubers of G. elata Bl. were processed under eight different protocols, and their resulting contents of potentially bioactive compounds were compared using liquid chromatography mass spectrometry to screen the potential quality markers of GR through stoichiometric analysis. The potential quality markers of GR targeting Alzheimer's disease, major depressive disorder, and cerebral ischemia were identified by network pharmacology, and the potentially neuroprotective effects of these components were validated through simulated docking to likely protein targets. Finally, a fit degree analysis was carried out using different composition ratios and proportions of the disease component degree value, and the therapeutic effects of different processing methods on Alzheimer's disease, major depressive disorder, and cerebral ischemia were outlined clearly.
Results: We identified 32 potential therapeutic components and screened 13 quality markers in GR, of which five quality markers (galactinol, glucosyringic acid, parishins C and E, and S-(4-hydroxybenzyl)-glutathione) showed efficacy against all three brain diseases. Furthermore, steaming and microwave-drying during processing can optimize the components of these quality markers for treating the three diseases.
Conclusion: Processing protocols significantly affect the therapeutic components of GR and may also impact its effectiveness in treating brain diseases. Accordingly, optimizing the processing methods of GR to correspond to different therapeutic purposes may improve its efficacy against brain diseases.
背景：天麻（Gastrodiae rhizoma，GR）是指天麻（Gastrodia elata Bl.）的干燥块茎，几个世纪以来一直被用于治疗阿尔茨海默病、重度抑郁症和脑缺血等脑部疾病。然而，GR 的加工工艺复杂多样，导致临床治疗效果不稳定。加工工艺对 GR 的有效成分和疗效有很大影响。我们可以通过确定质量标记来优化 GR 的加工过程，从而治疗脑部疾病：方法：用八种不同的方法加工新鲜的皂荚块茎，并用液相色谱质谱法比较其潜在生物活性化合物的含量，通过化学计量分析筛选出潜在的皂荚质量标记。通过网络药理学鉴定了针对阿尔茨海默病、重度抑郁症和脑缺血的潜在 GR 质量标志物，并通过模拟对接可能的蛋白质靶点验证了这些成分的潜在神经保护作用。最后，利用疾病成分度值的不同组成比和比例进行了拟合度分析，并清晰地勾勒出不同处理方法对阿尔茨海默病、重度抑郁症和脑缺血的治疗效果：结果：我们在 GR 中发现了 32 种潜在的治疗成分，并筛选出 13 种质量指标，其中 5 种质量指标（半乳糖苷醇、葡萄糖醛酸、维生素 C 和 E 以及 S-（4-羟基苄基）-谷胱甘肽）对这三种脑部疾病都有疗效。此外，加工过程中的蒸煮和微波干燥可以优化这些质量指标的成分，从而治疗这三种疾病：结论：加工方法会明显影响 GR 的治疗成分，也会影响其治疗脑部疾病的效果。因此，根据不同的治疗目的优化 GR 的加工方法可提高其对脑部疾病的疗效。
期刊介绍：
Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
